Craig E Gordon1, Claudia Nader. 1. aRenal Section, Department of Medicine, Boston University School of Medicine bDivision of Infectious Diseases, Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The current review highlights recent advances in treatment of chronic hepatitis C virus infection using new classes of agents, direct-acting antivirals (DAAs), with a focus on the evidence for their use in the setting of chronic kidney disease (CKD) stages 4-5, hemodialysis, and kidney transplantation. RECENT FINDINGS: DAA agents target-specific proteins involved in the hepatitis C virus life cycle and interrupt viral replication. Sustained virologic response, a marker of viral eradication, occurs in more than 90% of patients treated with DAA agents in the general population. Emerging data demonstrate similar sustained virologic response rates for specific DAA-based regimens in patients with CKD stages 4-5, hemodialysis patients, and kidney-transplant recipients. SUMMARY: High sustained virologic response rates are seen with DAA agents in CKD populations. A thoughtful approach to the timing of treatment is required to facilitate timely access to kidney transplantation.
PURPOSE OF REVIEW: The current review highlights recent advances in treatment of chronic hepatitis C virus infection using new classes of agents, direct-acting antivirals (DAAs), with a focus on the evidence for their use in the setting of chronic kidney disease (CKD) stages 4-5, hemodialysis, and kidney transplantation. RECENT FINDINGS:DAA agents target-specific proteins involved in the hepatitis C virus life cycle and interrupt viral replication. Sustained virologic response, a marker of viral eradication, occurs in more than 90% of patients treated with DAA agents in the general population. Emerging data demonstrate similar sustained virologic response rates for specific DAA-based regimens in patients with CKD stages 4-5, hemodialysis patients, and kidney-transplant recipients. SUMMARY: High sustained virologic response rates are seen with DAA agents in CKD populations. A thoughtful approach to the timing of treatment is required to facilitate timely access to kidney transplantation.
Authors: Debra T Choi; Amy Puenpatom; Xian Yu; Kevin F Erickson; Fasiha Kanwal; Hashem B El-Serag; Jennifer R Kramer Journal: Antiviral Res Date: 2019-12-17 Impact factor: 10.103